In English | En español
Questions About Cancer? 1-800-4-CANCER

Clinical Trials (PDQ®)

Page Options

  • Print This Page
  • Email This Document
Clinical Trial Questions?
Get Help:
1-800-4-CANCER
LiveHelp online chat

Clinical Trials (PDQ®)

Effect of NovoTTF-100A Together With Temozolomide in Newly Diagnosed Glioblastoma Multiforme (GBM)

Basic Trial Information
Trial Description
     Summary
     Further Trial Information
     Eligibility Criteria
Trial Contact Information

Basic Trial Information

PhaseTypeStatusAgeSponsorProtocol IDs
Phase IIITreatmentActive18 and overPharmaceutical / IndustryEF-14
NCT00916409

Trial Description

Summary

The study is a prospective, randomly controlled pivotal trial, designed to test the efficacy and safety of a medical device, the NovoTTF-100A, as an adjuvant to the best standard of care in the treatment of newly diagnosed GBM patients. The device is an experimental, portable, battery operated device for chronic administration of alternating electric fields (termed TTFields or TTF) to the region of the malignant tumor, by means of surface, insulated electrode arrays.

Further Study Information

PAST CLINICAL EXPERIENCE:

The effect of the electric fields generated by the NovoTTF-100A device (TTFields, TTF) has been tested in a large prospective, randomized trial, in recurrent GBM. The outcome of subjects treated with the NovoTTF-100A device was compared to those treated with an effective best standard of care chemotherapy (including bevacizumab). NovoTTF-100A subjects had comparable overall survival to subjects receiving the best available chemotherapy in the US today. Similar results showing comparability of NovoTTF-100A to BSC chemotherapy were seen in all secondary endpoints.

Recurrent GBM patients treated with the NovoTTF-100A device in this trial experienced fewer side effects in general, significantly fewer treatment related side effects, and significantly lower gastrointestinal, hematological and infectious adverse events compared to controls. The only device-related adverse events seen were a mild to moderate skin irritation beneath the device electrodes. Finally, quality of life measures were better in NovoTTF-100A subjects as a group when compared to subjects receiving effective best standard of care chemotherapy.

In a small scale pilot trial in newly diagnosed GBM patients, the treatment was well tolerated and suggested that NovoTTF-100A may improve time to disease progression and overall survival of newly diagnosed GBM patients. Although the number of patients in the pilot trial was small, The FDA has determined that the data gathered so far warrant testing of NovoTTF-100A treatment as a possible therapy for patients with newly diagnosed GBM.

DESCRIPTION OF THE TRIAL:

All patients included in this trial are newly diagnosed GBM patients who underwent a biopsy or surgery (with or without Gliadel wafers), followed by radiation therapy in combination with Temozolomide chemotherapy. In addition, all patients must meet all eligibility criteria.

Eligible patients will be randomly assigned to one of two groups:

1. Treatment with the NovoTTF-100A device in combination with Temozolomide chemotherapy.

2. Treatment with Temozolomide alone, as the best known standard of care.

Patients will be randomized at a 2:1 ratio (2 of every three patients who participate in the trial will be treated with the NovoTTF-100A device). Baseline tests will be performed in patients enrolled in both arms, including specific genetic tests done using tumor samples obtained during their initial surgery. If assigned to the NovoTTF-100A in combination with Temozolomide group, the patients will be treated continuously with the device until second progression. They will also receive temozolomide and possibly a second line treatment that can be one of the following: re-operation, local radiotherapy (gamma-knife), a second line of chemotherapy or a combination of the above.

NovoTTF-100A treatment will consist of wearing four electrically insulated electrode arrays on the head. Electrode array placement will require shaving of the scalp before and frequently during the treatment. After an initial short visit to the clinic for training and monitoring, patients will be released to continue treatment at home where they can maintain their regular daily routine.

During the trial, regardless of which treatment group the patient was assigned to, he or she will need to return once every month to the clinic where an examination by a physician and a routine laboratory examinations will be done. These routine visits will continue for as long as the patient's disease is not progressing for the second time under the study treatment. If such occurs, patients will need to return once per month for two more months to the clinic for similar follow up examinations.

During the visits to the clinic patients will be examined physically and neurologically. Additionally, routine blood tests will be performed. A routine MRI of the head will be performed at baseline and every second month thereafter, until second progression. After this follow up plan, patients will be contacted once per month by telephone to answer basic questions about their health status.

SCIENTIFIC BACKGROUND:

Electric fields exert forces on electric charges similar to the way a magnet exerts forces on metallic particles within a magnetic field. These forces cause movement and rotation of electrically charged biological building blocks, much like the alignment of metallic particles seen along the lines of force radiating outwards from a magnet.

Electric fields can also cause muscles to twitch and if strong enough may heat tissues. TTFields are alternating electric fields of low intensity. This means that they change their direction repetitively many times a second. Since they change direction very rapidly (200 thousand times a second), they do not cause muscles to twitch, nor do they have any effects on other electrically activated tissues in the body (brain, nerves and heart). Since the intensities of TTFields in the body are very low, they do not cause heating.

The breakthrough finding made by NovoCure was that finely tuned alternating fields of very low intensity, now termed TTFields (Tumor Treating Fields), cause a significant slowing in the growth of cancer cells. Due to the unique geometric shape of cancer cells when they are multiplying, TTFields cause the building blocks of these cells to move and pile up in such a way that the cells physically explode. In addition, cancer cells also contain miniature building blocks which act as tiny motors in moving essential parts of the cells from place to place. TTFields cause these tiny motors to fall apart since they have a special type of electric charge.

As a result of these two effects, cancer tumor growth is slowed and can even reverse after continuous exposure to TTFields.

Other cells in the body (normal healthy tissues) are affected much less than cancer cells since they multiply at a much slower rate if at all. In addition TTFields can be directed to a certain part of the body, leaving sensitive areas out of their reach.

In conclusion, TTField hold the promise of serving as a brand new cancer treatment with very few side effects and promising affectivity in slowing or reversing this disease.

Eligibility Criteria

Inclusion Criteria:

1. Pathological evidence of GBM using WHO classification criteria.

2. > 18 years of age.

3. Received maximal debulking surgery and radiotherapy concomitant with Temozolomide (45-70Gy):

1. Patients may enroll in the study if received Gliadel wafers before entering the trial

2. Any additional treatments received prior to enrollment will be considered an exclusion.

3. Minimal dose for concomitant radiotherapy is 45 Gy

4. Karnofsky scale ≥ 70

5. Life expectancy at least 3 months

6. Participants of childbearing age must use effective contraception.

7. All patients must sign written informed consent.

8. Treatment start date at least 4 weeks out from surgery.

9. Treatment start date at least 4 weeks out but not more than 7 weeks from the later of last dose of concomitant Temozolomide or radiotherapy.

Exclusion Criteria:

1. Progressive disease (according to MacDonald Criteria). If pseudoprogression is suspected, additional imaging studies must be performed to rule out true progression.

2. Actively participating in another clinical treatment trial

3. Pregnant

4. Significant co-morbidities at baseline which would prevent maintenance Temozolomide treatment:

1. Thrombocytopenia (platelet count < 100 x 103/μL)

2. Neutropenia (absolute neutrophil count < 1.5 x 103/μL)

3. CTC grade 4 non-hematological Toxicity (except for alopecia, nausea, vomiting)

4. Significant liver function impairment - AST or ALT > 3 times the upper limit of normal

5. Total bilirubin > upper limit of normal

6. Significant renal impairment (serum creatinine > 1.7 mg/dL)

5. Implanted pacemaker, programmable shunts, defibrillator, deep brain stimulator, other implanted electronic devices in the brain, or documented clinically significant arrhythmias.

6. Infra-tentorial tumor

7. Evidence of increased intracranial pressure (midline shift > 5mm, clinically significant papilledema, vomiting and nausea or reduced level of consciousness)

8. History of hypersensitivity reaction to Temozolomide or a history of hypersensitivity to DTIC.

Trial Contact Information

Trial Lead Organizations/Sponsors

Novocure Limited

Roger Stupp, MDStudy Director

Philip H. GutinStudy Director

Eric T. WongStudy Director

Herbert H. Engelhard, MD, PhDStudy Director

Manfred WestphalStudy Director

Ghazala Kabani
  Email: patientinfo@novocure.com

Trial Sites

U.S.A.
Alabama
  Birmingham
 UAB Comprehensive Cancer Center
 Thiru Pillay, RN Ph: 205-934-1842
  Email: tpillay@uabmc.edu
 Hassan Fathallah-Shaykh, MD, PhdPrincipal Investigator
Arizona
  Phoenix
 Barrow Neurology Clinics
 Andrea Ralph Ph: 602-406-6275
  Email: andrea.ralph@dignityhealth.org
 Lynn S. AshbyPrincipal Investigator
California
  Duarte
 City of Hope Comprehensive Cancer Center
 Alex Ching Ph: 626-471-9393
  Email: aching@coh.org
 Jana PortnowPrincipal Investigator
  La Jolla
 Rebecca and John Moores UCSD Cancer Center
 Pam Vranis Vranis Ph: 858-822-1847
  Email: pvranis@ucsd.edu
 Santosh Kesari, M.D., PhD.Principal Investigator
  Los Angeles
 USC/Norris Comprehensive Cancer Center and Hospital
 Lydia Wilson, NP Ph: 323-865-3945
  Email: lydia.wilson@med.usc.edu
 Thomas C. Chen, M.D., PhD.Principal Investigator
Colorado
  Aurora
 University of Colorado Cancer Center at UC Health Sciences Center
 Monica Robischon, RN Ph: 727-848-0661
  Email: Monica.robischon@ucdenver.edu
 Douglas E Ney, MDPrincipal Investigator
Florida
  Orlando
 Cancer Centers of Florida - Orlando
 Gayatri Nair, CCRP Ph: 321-841-7477
  Email: Gayatri.Nair@orlandohealth.com
 Nicholas G. Avgeropoulos, M.D.Principal Investigator
  Tampa
 H. Lee Moffitt Cancer Center and Research Institute at University of South Florida
 Allie Drew Ph: 813-745-3229
  Email: allie.drew@moffitt.org
 Nam D Tran, M.D.,Ph.D.Principal Investigator
Georgia
  Atlanta
 Winship Cancer Institute of Emory University
 Katarzyna "Kasia" Kopcewicz, CCRC Ph: 404-778-2981
  Email: kkopcew@emory.edu
 Willam Read, MDPrincipal Investigator
Illinois
  Chicago
 University of Illinois Cancer Center
 Joanna Hill Hill Ph: 312-996-9272
  Email: joanhill@uic.edu
 Herbert H. Engelhard, M.D., PhD.Principal Investigator
Kentucky
  Lexington
 Lucille P. Markey Cancer Center at University of Kentucky
 John Villano, MD, PhD Ph: 859-257-3379
  Email: jlvillano@uky.edu
 Tonya Gardner, CRC Ph: (859) 323-0532
  Email: tonya.gardner@uky.edu
 John Villano, MD, PhDPrincipal Investigator
  Louisville
 Norton Cancer Institute
 Leanne Coleman Ph: 502-629-4594
  Email: leanne.coleman@nortonhealthcare.org
 Renato V. LaRocca, MDPrincipal Investigator
Maine
  Scarborough
 Maine Medical Center Research Institute
 Debbie Cushing, R.N. Ph: 207-885-4438
  Email: cushid@mmc.org
 Rajiv Desai, M.D.Principal Investigator
Maryland
  Baltimore
 Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
 Sue Zhen Ph: 410-502-4081
  Email: Szhen1@jhmi.edu
 Alessandro Olivi, MDPrincipal Investigator
Massachusetts
  Boston
 Tufts Medical Center Cancer Center
 Amy Quinkert, PhD Ph: 617-636-8589
  Email: aquinkert@tuftsmedicalcenter.org
 Steven Hwang, MDPrincipal Investigator
  Burlington
 Lahey Clinic Medical Center - Burlington
 Christine Gould Ph: 781-744-3956
  Email: Christine.A.Gould@lahey.org
 Carlos A. David, M.D.Principal Investigator
Michigan
  Detroit
 Josephine Ford Cancer Center at Henry Ford Hospital
 Stephanie Marl Ph: 313-916-7231
  Email: SMARL1@hfhs.org
 Tobias Walbert, MD PhD MPHPrincipal Investigator
Missouri
  St. Louis
 Siteman Cancer Center at Barnes-Jewish Hospital - Saint Louis
 Abigail Gwinn Ph: 314-747-4678
  Email: AGwinn@dom.wustl.edu
 David D. Tran, MD, PhDPrincipal Investigator
New Jersey
  Edison
 New Jersey Neuroscience Institute at JFK Medical Center
 Charles Porbeni Ph: 732-321-7000 Ext.68897
  Email: cporbeni@jfkhealth.org
 Joseph C. LandolfiPrincipal Investigator
  Hackensack
 Hackensack University Medical Center Cancer Center
 Lori Cappello, RN,BSN Ph: 551-996-5098
  Email: LCappello@HackensackUMC.org
 Samuel Goldlust, MDPrincipal Investigator
New York
  New York
 Mount Sinai Medical Center
 Jean Hum, M.S. Ph: 212-824-7312
  Email: Jean.Hum@mssm.edu
 Isabelle M. Germano, MD, FACSPrincipal Investigator
 New York Weill Cornell Cancer Center at Cornell University
 Hanna D An Ph: 212-746-7373
  Email: haa3001@med.cornell.edu
 Susan PannulloPrincipal Investigator
Ohio
  Cleveland
 Cleveland Clinic Taussig Cancer Center
 Kathy Smolenski, RN BSN OCN Ph: 216-445-1067
  Email: smolenk2@ccf.org
 Gene Barnett, M.D.Principal Investigator
  Columbus
 Arthur G. James Cancer Hospital and Richard J. Solove Research Institute at Ohio State University Comprehensive Cancer Center
 Danette Birkhimer, MS, RN, OCN, CNS Ph: 614-293-2897
  Email: danette.birkhimer@osumc.edu
 Jill Brown Ph: 614-293-5554
  Email: Jill.brown@osumc.edu
 Herbert Newton, MDPrincipal Investigator
Pennsylvania
  Danville
 Geisinger Cancer Institute at Geisinger Health
 Angela Whitmire, RN Ph: 570-214-9603
  Email: awhitmire@geisinger.edu
 Steven A. Toms, M.D.Principal Investigator
  Philadelphia
 Hospital of the University of Pennsylvania
 Chau Nguyen Ph: 215-662-6832
  Email: Chau.Nguyen@uphs.upenn.edu
 Steven Brem, M.D.Principal Investigator
 Pennsylvania Hospital
 Marie T Kerr, CCRP Ph: 215-829-6720
  Email: kerm@uphs.upenn.edu
 John Lee, M.D.Principal Investigator
  Pittsburgh
 UPMC Cancer Centers
 Melinda Vargas-Jaffe Ph: 412-235-1320
  Email: vargasjaffema@upmc.edu
 Frank Scott LiebermanPrincipal Investigator
Texas
  Dallas
 Baylor University Medical Center - Dallas
 Amy Solis Ph: 214-820-8685
  Email: Amy.Solis@BaylorHealth.edu
 Sara Gonzales Ph: 214-820-6168
  Email: sara.gonzales@BaylorHealth.edu
 Karen L. Fink, M.D., PhD.Principal Investigator
 Simmons Comprehensive Cancer Center at University of Texas Southwestern Medical Center - Dallas
 Irma Smith, MS, CCRP Ph: 214-645-7212
  Email: irma.charles@utsouthwestern.edu
 Kevin Choe, M.D., Ph.D.Principal Investigator
  Houston
 Methodist Hospital
 Joan W Wan Ph: 713-534-1300
  Email: qwan2009@gmail.com
 Yvonne Kew, M.D., Ph.DPrincipal Investigator
 Kimbra Harris, CCRP Ph: 713-441-3834
  Email: KSHarris@houstonmethodist.org
 Pamela New, M.D.Principal Investigator
 University of Texas Health Science Center at Houston
 GuangRong Greg Lu Ph: 713-704-2359
  Email: GuangRong.Lu@uth.tmc.edu
 Jay-Jiguang Zhu, M.D., Ph.D.Principal Investigator
  Temple
 Scott and White Cancer Institute
 Melissa Ainslie Ph: 254-724-5679
  Email: MAINSLIE@sw.org
 Ekokobe Fonkem, D.O.Principal Investigator
  The Woodlands
 Memorial Hermann The Woodlands
 GuangRong Greg Lu Ph: 713-704-2359
  Email: GuangRong.Lu@uth.tmc.edu
 Jay-Jiguang Zhu, MD, PHDPrincipal Investigator
Virginia
  Charlottesville
 University of Virginia Cancer Center
 Johanna Loomba Ph: 434-924-5859
  Email: JJL4D@hscmail.mcc.virginia.edu
 David SchiffPrincipal Investigator
Washington
  Seattle
 Seattle Cancer Care Alliance
 Ashley Waldie Ph: 206-685-5597
  Email: awaldie@seattlecca.org
 Maciej M MrugalaPrincipal Investigator
 Swedish Cancer Institute at Swedish Medical Center - First Hill Campus
 Becky Wood Ph: 206-320-7115
  Email: becky.wood@swedish.org
 John Henson, MDPrincipal Investigator
Austria
  Graz
 Landeskrankenhaus/Universitatskliniken Graz
 Franz Payer, Prof. Ph: +43 (0) 316 385-80388
  Email: franz.payer@meduni-graz.at
 Franz Payer, M.D.Principal Investigator
  Vienna
 Allgemeines Krankenhaus - Universitatskliniken
 Christine Marosi, MD Ph: +43 1 40400 4421
  Email: christine.marosi@meduniwien.ac.at
 Christine Marosi, MDPrincipal Investigator
 SMZ-Süd/Kaiser-Franz-Josef-Spital
 Wolfgang Grisold, MD Ph: +43 1 60191 2008
  Email: wolfgang.grisold@wienkav.at
 Wolfgang Grisold, MDPrincipal Investigator
Canada
Alberta
  Calgary
 Tom Baker Cancer Centre - Calgary
 Debra Rich Ph: 403-521-3031
  Email: Debra.Rich@AlbertaHealthServices.ca
 Jacob Easaw, MD, PhD, FRCP(C)Principal Investigator
Manitoba
  Winnipeg
 CancerCare Manitoba
 Kathi Klapp Ph: 204-787-2159
  Email: Kathi.Klapp@cancercare.mb.ca
 Marshall PitzPrincipal Investigator
Ontario
  Hamilton,
 Margaret and Charles Juravinski Cancer Centre
 Hal Hirte Ph: 905-387-9495
 Hal W. HirtePrincipal Investigator
  Ottawa
 Ottawa Hospital Regional Cancer Centre - General Campus
 Heather Sharpe Ph: (613) 737-7700 Ext.73281
  Email: hsharpe@toh.on.ca
 Garth Nicholas, MD, FRCPCPrincipal Investigator
Quebec
  Montreal
 Hopital Notre-Dame du CHUM
 Diane Trudel Ph: 514-890-8000 Ext.26906
  Email: diane.dt.trudel.chum@ssss.gouv.qc.ca
 David RobergePrincipal Investigator
 McGill - Gerald Bronfman Centre for Clinical Research in Oncology -
 Beatrice Fournier, PhD, CCRP Ph: 514-340-8222 Ext.6771
  Email: bfournier@jgh.mcgill.ca
 Thierry Muanza, M.D.Principal Investigator
 Montreal Neurological Institute
 Lisa Nezvitsky, M.Sc. Ph: (514) 398-2801
 Scott OwenPrincipal Investigator
  Sherbrooke
 (CHUS) Centre Hospitalier Universitaire de Sherbrooke, Service de Neurochirurgie
 Anick Champoux Ph: 819-346-1110 Ext.12811
  Email: achampoux.chus@ssss.gouv.qc.ca
 David MathieuPrincipal Investigator
Czech Republic
  Prague
 Nemocnice Na Homolce
 Jan Sroubek, M.D. Ph: +420 (25727) 3091
  Email: Jan.Sroubek@homolka.cz
 Jan Sroubek, M.D.Principal Investigator
France
  Amiens
 CHU Amiens - Hopital Sud
 Mathieu Boone, MD Ph: +33 32 245 5499
  Email: Boone.Mathieu@chu-amiens.fr
 Mathieu Boone, MDPrincipal Investigator
  Angers
 Centre Hospitalier Regional et Universitaire d'Angers
 Marie-Anne Poiron Ph: +33 02 4135 48 22
  Email: MAPoiron@chu-angers.fr
 Philippe Menei, MD, PhDPrincipal Investigator
  Bordeaux
 Hopital Saint Andre
 Emilie Wallet, SC Ph: +33 05 57 82 13 04
  Email: emilie.wallet@chu-bordeaux.fr
 Isabelle Catry-Thomas, MDPrincipal Investigator
  Lyon
 Hospital of Neurology Pierre Wertheimer
 Linda Chami Ph: +33 04 72 35 58 42
  Email: linda.chami@chu.lyon.fr
 Jerome Honnorat, M.D.Principal Investigator
  Paris
 CHU Pitie-Salpetriere
 Louise Anemet Ph: +33 142 16 04 04
  Email: louise.anemet@psl.aphp.fr
 Ahmed Idbaih, M.D.Principal Investigator
  Toulouse
 Centre Hospitalier Regional de Purpan
 Dr. Alexandra Benouaich-Amiel, M.D. Ph: +33 (0)5 61 77 22 71
  Email: benouaich-amiel.a@chu-toulouse.fr
 Alexandra Benouaich-Amiel, MDPrincipal Investigator
Germany
  Hamburg
 University Medical Center Hamburg - Eppendorf
 Manfred Westphal, M.D. Ph: +49 (40) 7410 53750
 Manfred Westphal, M.D.Principal Investigator
  Heidelberg
 Medical University Heidelberg
 Barbara Stöhr Ph: +49 6221 56 37243
  Email: barbara.stoehr@med.uni-heidelberg.de
 Wolfgang Wick, MDPrincipal Investigator
  Kiel
 University Hospital Schleswig-Holstein - Kiel Campus
 Maximillian Mehdorn, M.D, PhD. Ph: 0049 431 597 4800
  Email: mehdorn@nch.uni-kiel.de
 Maximilian Mehdorn, M.D.Principal Investigator
Israel
  Tel Aviv
 Tel-Aviv Sourasky Medical Center
 Carmit Ben Harosh Ph: 972 52 426 2245
  Email: carmitbh@tasmc.health.gov.il
 Andrew Kanner, M.D.Principal Investigator
Italy
  Ancona
 Ospedale Generale Umberto 1
 Massimo Scerrati, MD Ph: +39 0715964578
  Email: m.scerrati@univpm.it
 Massimo Scerrati, MDPrincipal Investigator
  Lecco
 Ospedale Alessandro Manzoni
 Andrea Salmaggi Ph: 0039 0341 489111
  Email: a.salmaggi@ospedale.lecco.it
 Andrea Salmaggi, MDPrincipal Investigator
  Milan
 Istituto Nazionale Neurologico Carlo Besta
 Paola Gaviani, M.D. Ph: 0039 02 2394 2440
  Email: paola.gaviani@istituto-besta.it
 Antonio Silvani, M.D. Ph: +39 (022394) 23051
  Email: Antonio.Silvani@istituto-besta.it
 Antonio Silvani, M.D.Principal Investigator
 Ospedale Maggiore Policlinico
 Manuela Caroli, M.D. Ph: 0039 02 55035528
  Email: man.caroli@tin.it
 Manuela Caroli, MDPrincipal Investigator
  Rome
 Istituto Regina Elena
 Carmine Carapella, M.D. Ph: +39 06 52665595
  Email: carapella@ifo.it
 Carmine Carapella, M.D.Principal Investigator
Republic of Korea
  Asan
 Asan Medical Center
 Ji-Young Suh Ph: +82-2-3010-7364
  Email: jysuh@amc.seoul.kr
 Se Hyuk Kim, Prof.Principal Investigator
  Daegu
 Yeungnam University Hospital
 Bo-Nam Seo Ph: +82-53-624-8354
 Oh Lyong Kim, Prof.Principal Investigator
  Daejeon
 Chungnam National University Hospital (CNUH)
 Joo-Young Lee Ph: +82-42-280-7399
  Email: ljy99@cnuh.co.kr
 Hwan Jung Yun, Prof.Principal Investigator
  Seoul
 Samsung Medical Center (SMC)
 Sangok Park Ph: +82 2 3410 0867
  Email: sangok8133.park@samsung.com
 Dohyun Nam, Prof.Principal Investigator
 Seoul National University Bundang Hospital
 Eun-jin Choi Ph: +82-31-787-6001
  Email: r0415@snubh.org
 Chae Yong Kim, Prof.Principal Investigator
 Seoul National University Hospital
 Mi-Yeon Yoo Ph: +82-2-2072-3993
 Sun Ha Peak, Prof.Principal Investigator
 The Catholic University of Korea, Seoul St. Mary's Hospital (CMC Seoul)
 Sun-Mi Hyun Ph: +82 2 2258 3054
 David Jae
 Yong Kil Hong, Prof.Principal Investigator
 Yonsei Cancer Center at Yonsei University Medical Center
 Hyunsim Park Ph: +82 2 2227 7867
 Se Hoon Kim
 Jong-Hee Chang, Prof.Principal Investigator
  Suwon
 Ajou University Hospital
 Joolee Park Ph: +82-31-219-4266
 Se Hyuk Kim, Prof.Principal Investigator
Spain
  Badalona
 Hospital Universitari Germans Trias i Pujol
 Salvador Villa Freixa, MD Ph: +34 93 497 88 05
  Email: svilla@iconcologia.net
 Salvador Villa Freixa, MDPrincipal Investigator
  Barcelona
 Hospital Clinic de Barcelona
 Teresa Vilella, SC Ph: +34 93 227 54 00 Ext.2811
  Email: vilella@clinic.cat
 Francesc Graus Graus, MDPrincipal Investigator
 Hospital Del Mar
 María Martínez García, MD Ph: '+34 93 248 38 62
  Email: MariaMartinezGarcia@parcdesalutmar.cat
 María Martínez García, MDPrincipal Investigator
 Hospital Universitari de Bellvitge-ICO Duran i Reynals
 Jordi Bruna Escuer, MD, PhD Ph: +34 93 2607711
  Email: 35078jbe@comb.cat
 Jordi Bruna Escuer, MD, PhDPrincipal Investigator
  Madrid
 Fundacion Jimenes Diaz
 Jose de Campos, MD Ph: +34 659 574 378
  Email: JMcampos@fjd.es
 Jose de Campos, MDPrincipal Investigator
 Hospital 12 de Octubre, Servicio de Oncología Médica
 Dr. J.M. Sepulveda, MD Ph: +34 91 390 80 03
 Dr. J.M. Sepúlveda, MDPrincipal Investigator
 Hospital Universitario Ramon y Cajal
 Maria de los Angeles Vaz, MD Ph: +34 91 336 82 63
  Email: mavaz3@yahoo.es
 Maria de los Angeles Vaz, MDPrincipal Investigator
 Hospital Universitario San Carlos
 Pedro Perez Segura, MD Ph: +34 91330364
  Email: perezsegura09@gmail.com
 Pedro Perez Segura, MDPrincipal Investigator
  Pamplona
 Clínica Universidad de Navarra
 Jaime Gallego Perez-Larraya, MD Ph: +34 948 25 54 00
  Email: jgallego@unav.es
 Jaime Gallego Perez-Larraya, MDPrincipal Investigator
Sweden
  Stockholm
 Karolinska University Hospital - Huddinge
 Giuseppe Stragliotto, MD Ph: +46 (0)8-517 72072
  Email: giuseppe.stragliotto@karolinska.se
 Giuseppe Stragliotto, MDPrincipal Investigator
Switzerland
  Lausanne
 Centre Hospitalier Universitaire Vaudois
 Alexandra Rideau Ph: +(41) 21 314 7629
  Email: Alexandra.Rideau@chuv.ch
 Andreas Hottinger, M.D.Principal Investigator
  Zurich
 UniversitaetsSpital Zuerich
 Tanja Pendl Ph: +41 44 255 5362
  Email: tanja.pendl@usz.ch
 Michael Weller, MDPrincipal Investigator

Link to the current ClinicalTrials.gov record.
NLM Identifer NCT00916409
ClinicalTrials.gov processed this data on November 12, 2014

Note: Information about this trial is from the ClinicalTrials.gov database. The versions designated for health professionals and patients contain the same text. Minor changes may be made to the ClinicalTrials.gov record to standardize the names of study sponsors, sites, and contacts. Cancer.gov only lists sites that are recruiting patients for active trials, whereas ClinicalTrials.gov lists all sites for all trials. Questions and comments regarding the presented information should be directed to ClinicalTrials.gov.

Back to TopBack to Top